Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/15/2024 | $7.00 → $5.00 | Buy → Hold | Craig Hallum |
| 8/6/2024 | Overweight → Equal-Weight | Morgan Stanley | |
| 8/6/2024 | Buy → Neutral | BTIG Research | |
| 8/6/2024 | Overweight → Neutral | JP Morgan | |
| 6/21/2024 | $7.50 | Buy | Craig Hallum |
| 12/14/2023 | Neutral | Guggenheim | |
| 7/5/2023 | $18.00 | Overweight | JP Morgan |
| 2/2/2023 | $14.00 | Buy | UBS |
SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)
SC 13G - Akoya Biosciences, Inc. (0001711933) (Subject)
SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)
MARLBOROUGH, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the third quarter ending September 30, 2024. "Our third-quarter results came in below expectations, largely due to ongoing capital equipment purchase constraints seen across the life science tools market. We remain optimistic about the long-term growth outlook of our industry, but we recognize the current environment will pose temporary challenges. We proactively anticipated this with our recent organizational restructuring, which, while difficult and temporarily disruptive this quarter, was the right decision and en
Pre-orders now available; early access available for select strategic partners for the PhenoCode IO60 panel – The Fastest Ultrahigh-plex Panel for Immuno-Oncology Research Launches the Mouse FFPE IO panel, optimized for pre-clinical immuno-oncology applications to drive translational research insights Expands the PhenoCode catalog with barcodes that enable ultrahigh-plex, 100-biomarker experiments, making scalable spatial biology research accessible for every lab MARLBOROUGH, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company ®, will unveil innovations designed to accelerate insights in immuno-oncology (IO) and advance p
MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2024 after the market closes on Thursday, November 14, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Akoya website at https://investors.akoyabio.com/. About A
4 - Akoya Biosciences, Inc. (0001711933) (Issuer)
4 - Akoya Biosciences, Inc. (0001711933) (Issuer)
4 - Akoya Biosciences, Inc. (0001711933) (Issuer)
10-Q - Akoya Biosciences, Inc. (0001711933) (Filer)
8-K - Akoya Biosciences, Inc. (0001711933) (Filer)
8-K - Akoya Biosciences, Inc. (0001711933) (Filer)
Joe Driscoll to Retire After More than Four Successful Years as Chief Financial Officer Johnny Ek Appointed as new Chief Financial Officer MARLBOROUGH, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that Chief Financial Officer Joe Driscoll is retiring from his position, effective March 20, 2023. Johnny Ek has been appointed as the company's new Chief Financial Officer, effective immediately. Mr. Driscoll will continue to serve as a consultant of the company as Akoya executes a seamless transition between the two leaders. Mr. Driscoll joined Akoya in April 2019 and has overseen the company's financ
MARLBOROUGH, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced the appointment of Jennifer Kamocsay as General Counsel. Ms. Kamocsay will oversee all company legal activities and provide strategic guidance and corporate governance oversight. "We are excited to welcome Jennifer to our leadership team," said Brian McKelligon, Chief Executive Officer of Akoya. "Her deep legal expertise and insight will be invaluable as we continue to advance our spatial biology platform and establish additional partnerships to support discovery, translational, and clinical markets." Ms. Kamocsay most recently served as Gen
MARLBOROUGH, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced the appointment of Dr. Ehab A. El-Gabry as the company's Chief Medical Officer (CMO). In this newly created position, Dr. El-Gabry will lead Akoya's strategy in advancing the use of its spatial phenotyping solutions in the clinical setting. Dr. El-Gabry brings a wealth of experiences that are critical to the company's vision of advancing spatial phenotyping in precision medicine and cancer care. He is a board-certified pathologist who served as the Senior Medical Director for Roche Tissue Diagnostics Personalized Health Care Solutions (PHCS). As the
Craig Hallum downgraded Akoya Biosciences from Buy to Hold and set a new price target of $5.00 from $7.00 previously
Morgan Stanley downgraded Akoya Biosciences from Overweight to Equal-Weight
BTIG Research downgraded Akoya Biosciences from Buy to Neutral
Ratings for Akoya Biosciences (NASDAQ:AKYA) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 2 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 1 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $6.5, along with a high estimate of $10.00 and a low estimate of $4.00. Observing a downward t
Morgan Stanley analyst Tejas Savant maintains Akoya Biosciences (NASDAQ:AKYA) with a Overweight and lowers the price target from $8 to $4.
Canaccord Genuity analyst Kyle Mikson maintains Akoya Biosciences (NASDAQ:AKYA) with a Buy and lowers the price target from $10 to $6.
MARLBOROUGH, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the third quarter ending September 30, 2024. "Our third-quarter results came in below expectations, largely due to ongoing capital equipment purchase constraints seen across the life science tools market. We remain optimistic about the long-term growth outlook of our industry, but we recognize the current environment will pose temporary challenges. We proactively anticipated this with our recent organizational restructuring, which, while difficult and temporarily disruptive this quarter, was the right decision and en
MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2024 after the market closes on Thursday, November 14, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Akoya website at https://investors.akoyabio.com/. About A
MARLBOROUGH, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the second quarter ending June 30, 2024. "Our second-quarter revenue showed a strong rebound with 26% sequential top-line growth and a stable year-over-year performance," said Brian McKelligon, CEO of Akoya Biosciences. "We believe that Akoya's platforms are poised to lead the spatial biology market from discovery to diagnostics, while we also position the company to achieve near-term operating cash flow breakeven as we align our cost structure with our strategic objectives." Second Quarter 2024 Financial and Bu